MX355474B - Compuestos de heterociclilo como inhibidores de mek. - Google Patents
Compuestos de heterociclilo como inhibidores de mek.Info
- Publication number
- MX355474B MX355474B MX2014010928A MX2014010928A MX355474B MX 355474 B MX355474 B MX 355474B MX 2014010928 A MX2014010928 A MX 2014010928A MX 2014010928 A MX2014010928 A MX 2014010928A MX 355474 B MX355474 B MX 355474B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- mek inhibitors
- heterocyclyl compounds
- formula
- present disclosure
- Prior art date
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN288KO2012 | 2012-03-14 | ||
| PCT/IB2013/051908 WO2013136249A1 (en) | 2012-03-14 | 2013-03-11 | Heterocyclyl compounds as mek inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010928A MX2014010928A (es) | 2015-04-10 |
| MX355474B true MX355474B (es) | 2018-04-16 |
Family
ID=47997632
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010928A MX355474B (es) | 2012-03-14 | 2013-03-11 | Compuestos de heterociclilo como inhibidores de mek. |
| MX2018003665A MX366426B (es) | 2012-03-14 | 2013-03-11 | Compuestos de heterociclilo como inhibidores de mek. |
| MX2014010925A MX355526B (es) | 2012-03-14 | 2013-03-11 | Compuesto de heterociclilo. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003665A MX366426B (es) | 2012-03-14 | 2013-03-11 | Compuestos de heterociclilo como inhibidores de mek. |
| MX2014010925A MX355526B (es) | 2012-03-14 | 2013-03-11 | Compuesto de heterociclilo. |
Country Status (35)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| JP6093384B2 (ja) | 2012-03-14 | 2017-03-08 | ルピン・リミテッド | ヘテロシクリル化合物 |
| SG11201408238WA (en) | 2012-06-13 | 2015-01-29 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| KR102222569B1 (ko) * | 2013-10-25 | 2021-03-05 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 피리딘의 케톤 유도체의 제조 방법 및 제약 용도 |
| WO2016009306A1 (en) * | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| WO2016035008A1 (en) * | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MX388991B (es) | 2015-02-20 | 2025-03-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr) |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| JP7219218B2 (ja) | 2016-12-22 | 2023-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JOP20200154A1 (ar) | 2017-12-21 | 2020-06-18 | Boehringer Ingelheim Int | مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1 |
| JP7568512B2 (ja) | 2018-05-04 | 2024-10-16 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の塩 |
| KR20210018265A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 고체 형태 및 이의 제조 방법 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020254451A1 (en) | 2019-06-19 | 2020-12-24 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020323687A1 (en) * | 2019-07-30 | 2022-02-17 | Edvince Ab | MEK inhibitor for treatment of stroke |
| EP3797899A1 (de) | 2019-09-27 | 2021-03-31 | Primetals Technologies Austria GmbH | Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4157836B1 (en) | 2020-06-02 | 2025-10-29 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TWI825637B (zh) * | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| WO2022214594A1 (en) | 2021-04-09 | 2022-10-13 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| IL307673A (en) * | 2021-04-16 | 2023-12-01 | Ikena Oncology Inc | MEK inhibitors and their use |
| EP4346826A4 (en) | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| US12428420B2 (en) | 2021-06-09 | 2025-09-30 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023099592A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099608A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118591540A (zh) | 2021-12-01 | 2024-09-03 | 勃林格殷格翰国际有限公司 | 包含环状2-氨基-3-氰基噻吩的kras降解化合物 |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099623A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN114573581B (zh) * | 2022-03-30 | 2023-09-01 | 沈阳药科大学 | 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114573582B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用 |
| CN114456166B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| CN119768393A (zh) | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| WO2024246099A1 (en) | 2023-05-30 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| UA72612C2 (en) * | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US6825180B2 (en) * | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
| ATE314370T1 (de) * | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| SG149033A1 (en) | 2003-11-19 | 2009-01-29 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
| RS50569B (sr) | 2004-06-11 | 2010-05-07 | Japan Tobacco Inc. | Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| AU2009344690A1 (en) | 2009-04-21 | 2011-10-27 | Novartis Ag | Heterocyclic compounds as MEK inhibitors |
| JP6093384B2 (ja) * | 2012-03-14 | 2017-03-08 | ルピン・リミテッド | ヘテロシクリル化合物 |
-
2013
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/ja active Active
- 2013-03-11 MX MX2014010928A patent/MX355474B/es active IP Right Grant
- 2013-03-11 CA CA2865164A patent/CA2865164C/en active Active
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 ES ES13712929T patent/ES2684517T3/es active Active
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/ja active Active
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/pt active IP Right Grant
- 2013-03-11 PL PL13712929T patent/PL2834237T3/pl unknown
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/da active
- 2013-03-11 MX MX2018003665A patent/MX366426B/es unknown
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/zh active Pending
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/ko active Active
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/ko not_active Expired - Fee Related
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/es unknown
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/en active Active
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/tr unknown
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/en active Active
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/ko not_active Ceased
- 2013-03-11 MA MA37405A patent/MA37405A1/fr unknown
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/xx unknown
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/es active IP Right Grant
- 2013-03-11 UA UAA201411014A patent/UA114907C2/uk unknown
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 MX MX2014010925A patent/MX355526B/es active IP Right Grant
- 2013-03-11 MA MA37400A patent/MA37400B1/fr unknown
- 2013-03-11 UA UAA201411011A patent/UA114906C2/uk unknown
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/zh active Active
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/zh active Pending
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
- 2013-03-11 ES ES13711973T patent/ES2741896T3/es active Active
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/es active IP Right Grant
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/en not_active Ceased
- 2013-03-11 EA EA201491672A patent/EA028232B1/ru unknown
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/ko not_active Ceased
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 EA EA201491671A patent/EA029768B1/ru unknown
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/en not_active Ceased
- 2013-03-11 CA CA2865167A patent/CA2865167C/en not_active Expired - Fee Related
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/zh active Pending
-
2014
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/fr unknown
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/fr unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/es unknown
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/es unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/es unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/es unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040B1/en unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/es unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/es unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/es unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/es unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041A1/en unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/es unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/es unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/es unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/es unknown
-
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
-
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
-
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502041A1 (en) | Heterocyclyl compounds as mek inhibitors | |
| MX360634B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. | |
| IN2014DN09434A (en:Method) | ||
| PH12014502524B1 (en) | Carboxylic acid compounds | |
| EA201201680A1 (ru) | Морфолинопиримидины и их применение в терапии | |
| NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
| IN2014MN02598A (en:Method) | ||
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| IN2015DN01156A (en:Method) | ||
| EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
| IN2015DN01119A (en:Method) | ||
| EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| EA201491878A1 (ru) | Замещенные ксантиновые производные | |
| UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |